Fig 2 - available via license: Creative Commons Attribution-NonCommercial 4.0 International
Content may be subject to copyright.
T-cell receptor V beta gene repertoire analysis. Naïve, effector, and memory CTLs are shown in the upper, middle, and lower panels, respectively. Peripheral blood mononuclear cells were analyzed by flow cytometry using the Beta Mark TCR Vβ repertoire kit (Beckman Coulter, Tokyo, Japan) according to the manufacturer's instructions. Naïve CTLs were defined as the CD8+CD27+CD45RA+ population, effector CTLs were defined as the CD8+CD27-CD45RA+ population, and memory CTLs were defined as the CD8+CD45RA-population. Vb, V beta; Mo, months after starting dasatinib.
Source publication
We present the case of a patient with multiple tyrosine kinase inhibitor (TKI)-refractory chronic phase chronic myeloid leukemia (CP-CML) with a T315I mutation of abl1. Dasatinib, a second-generation TKI, was administered as the initial treatment but achieved neither a cytogenetic nor molecular response. A mutational analysis of abl1 revealed that...
Contexts in source publication
Context 1
... investigate the cellular immunity, T-cell receptor (TCR) V beta gene repertoire analyses were performed using flow cytometry targeting CD8-positive T cells at several time points (Fig. 2). We detected fairly high percentages of naïve and effector CTLs using TCR V beta 13.6 at the seventh month after starting dasatinib (naïve CTLs, 33.5%; effector CTLs, 71.9%). The percentages of naïve CTLs subsequently showed a gradual increase to approximately 70%, while the percentages of the effector CTLs remained at the same level ...
Similar publications
Purpose
Chronic Myeloid Leukemia (CML) is a clonal disorder of the hematopoietic stem cell caused by expression of the BCR::ABL1 oncoprotein. High BCR::ABL1 levels have been associated to proliferative advantage of leukemic cells, blast crisis progression and tyrosine kinase inhibitors (TKIs) inefficacy. We have previously shown that high BCR::ABL1...
Background
Immunological phenotypes and differentiation statuses commonly decide the T cell function and anti-tumor ability. However, little is known about these alterations in CML patients.
Method
Here, we investigated the immunologic phenotypes (CD38/CD69/HLA-DR/CD28/CD57/BTLA/TIGIT/PD-1) of T subsets (TN, TCM, TEM, and TEMRA) in peripheral bloo...
Background
Chronic myeloid leukemia (CML) is characterized by the presence of BCR::ABL1 fusion gene resulting from a reciprocal translocation, t(9;22)(q34;q11.2), leading to prominent granulocytic proliferation. The majority of patients initially present in chronic phase (CP), which may progress to advanced CML with predominantly granulocytic pheno...
Background
Dasatinib and other tyrosine kinase inhibitors (TKI) have revolutionized the treatment of chronic myeloid leukemia (CML). However, as a lipophilic weak base, crystalline monohydrate, dasatinib (Sprycel®) is poorly soluble, rendering a pH‐dependent absorption and a highly variable bioavailability. Thus, co‐medication with proton pump inhi...
We present the case of an 85-year-old male patient diagnosed with human herpesvirus 8 (HHV8)-negative effusion-based lymphoma (EBL) that developed from long-lasting pleural effusion (PE) induced by dasatinib treatment for chronic myeloid leukemia (CML). After the onset of this disorder, dasatinib treatment was discontinued and drainage was performe...
